Table 5.
Clinicopathological features of patients based on EGFR/CD8 status.
| Characteristics | Total cases | EGFR+ | p-value | Total cases | EGFR- | p-value | ||
|---|---|---|---|---|---|---|---|---|
| CD8+ | CD8- | CD8+ | CD8- | |||||
| Number of Cases | 58 | 39 (67.24%) | 19 (32.76%) | 80 | 50 (62.5%) | 30 (37.5%) | ||
| Sex | ||||||||
| Male | 33 | 26 (66.67%) | 7 (36.84%) | 0.03 | 45 | 29 (58%) | 16 (53.33%) | 0.68 |
| Female | 25 | 13 (33.33%) | 12 (63.16%) | 35 | 21 (42%) | 14 (46.67%) | ||
| Average Age [± stdev]* | ||||||||
| Male | 33 | 59.08 [13.21] | 53.57 [13.24] | 0.06 | 45 | 58 [9.72] | 57.63 [10.66] | 0.18 |
| Female | 25 | 63 [19.28] | 71.42 [11.60] | 35 | 65.67 [20.74] | 65.5 [15] | ||
| Smoking History | ||||||||
| Active smoker | 23 | 13 (33.33%) | 10 (52.63%) | 0.66 | 36 | 20 (40.82%) | 16 (53.33%) | 0.41 |
| Never smoker | 22 | 16 (41.03%) | 6 (31.58%) | 25 | 16 (32.65%) | 9 (30%) | ||
| Quit < 10 Years | 3 | 3 (7.69%) | 0 (0%) | 10 | 6 (12.24%) | 4 (13.33%) | ||
| Quit > 10 Years | 10 | 7 (17.95%) | 3 (15.79%) | 8 | 7 (14.29%) | 1 (3.33%) | ||
| N/A | 1 | |||||||
| Tumor Site | ||||||||
| Alveolar | 9 | 7 (17.95%) | 2 (10.53%) | 0.05 | 12 | 9 (18%) | 3 (10%) | 0.40 |
| Floor of mouth | 10 | 5 (12.82%) | 5 (26.32%) | 19 | 9 (18%) | 10 (33.33%) | ||
| Tongue | 27 | 22 (56.41%) | 5 (26.32%) | 27 | 17 (34%) | 10 (33.33%) | ||
| Other | 12 | 5 (12.82%) | 7 (36.84%) | 22 | 15 (30%) | 7 (23.33%) | ||
| T Stage | ||||||||
| T1 | 22 | 15 (38.46%) | 7 (36.84%) | 0.63 | 21 | 15 (30%) | 6 (20%) | 0.60 |
| T2 | 16 | 12 (30.77%) | 4 (21.05%) | 23 | 14 (28%) | 9 (30%) | ||
| T3/T4 | 20 | 12 (30.77%) | 8 (42.11%) | 36 | 21 (42%) | 15 (50%) | ||
| N Stage | ||||||||
| N0 | 26 | 20 (51.28%) | 6 (31.58%) | 0.34 | 44 | 29 (58%) | 15 (50%) | 0.75 |
| N1/2a | 16 | 9 (23.08%) | 7 (36.84%) | 11 | 6 (12%) | 5 (16,67%) | ||
| N2b/2c/3 | 16 | 10 (25.64%) | 6 (31.58%) | 25 | 15 (30%) | 10 (33.33%) | ||
| Differentiation | ||||||||
| Well | 3 | 3 (7.89%) | 0 (0%) | 0.28 | 12 | 8 (16.32%) | 4 (13.33%) | 0.74 |
| Moderate | 37 | 22 (57.89%) | 15 (83.33%) | 47 | 30 (61.22%) | 17 (56.67%) | ||
| Poor | 16 | 13 (34.21%) | 3 (16.67%) | 20 | 11 (22.45%) | 9 (30%) | ||
| N/A | 2 | 1 | ||||||
| Perineural invasion | ||||||||
| Yes | 35 | 23 (58.97%) | 12 (63.16%) | 0.76 | 38 | 21 (42%) | 17 (56.67%) | 0.2 |
| No | 23 | 16 (41.03%) | 7 (36.84%) | 42 | 29 (58%) | 13 (43.33%) | ||
| Lymphovascular invasion | ||||||||
| Yes | 25 | 15 (38.46%) | 10 (52.63%) | 0.31 | 28 | 17 (34%) | 11 (36.67%) | 0.81 |
| No | 33 | 24 (61.54%) | 9 (47.37%) | 52 | 33 (66%) | 19 (63.33%) | ||
| Bone invasion | ||||||||
| Yes | 14 | 9 (23.08%) | 5 (26.32%) | 0.79 | 27 | 18 (36%) | 9 (30%) | 0.58 |
| No | 44 | 30 (76.92%) | 14 (73.68%) | 53 | 32 (64%) | 21 (70%) | ||
| Local recurrence | ||||||||
| Yes | 19 | 13 (33.33%) | 6 (31.58%) | 0.89 | 25 | 16 (32%) | 9 (30%) | 0.85 |
| No | 39 | 26 (66.67%) | 13 (68.42%) | 55 | 34 (68%) | 21 (70%) | ||
*Average age at diagnosis.